| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The NHS ester functional group on ATTO 425 NHS ester targets primary amines (-NH₂) on biomolecules such as proteins, antibodies, and peptides. The compound does not target specific enzymes or receptors but serves as a covalent labeling reagent that attaches the ATTO 425 fluorophore to amine-containing biomolecules.
|
|---|---|
| ln Vitro |
The in vitro activity of ATTO 425 NHS ester is characterized by its strong blue fluorescence, with excitation and emission maxima around 436 nm and 484 nm, respectively. The dye exhibits high fluorescence quantum yield and photostability, making it suitable for various fluorescence-based detection and imaging applications.
|
| ln Vivo |
ATTO 425 NHS ester is not used as a therapeutic agent. Its in vivo utility is as a labeling reagent for fluorescence imaging applications. When conjugated to targeting ligands, the dye enables fluorescence imaging for tracking biomolecules in biological samples.
|
| Enzyme Assay |
In vitro labeling assays for ATTO 425 NHS ester involve incubating the NHS ester with amine-containing biomolecules in appropriate buffers (typically pH 7-9). The reaction proceeds through nucleophilic attack of the primary amine on the NHS ester carbonyl, forming a stable amide bond. Labeling efficiency can be assessed by measuring the fluorescence intensity of the conjugated product.
|
| Cell Assay |
For in vitro cellular experiments, ATTO 425 NHS ester is first conjugated to antibodies, proteins, or other targeting ligands via the NHS ester-amine reaction. The labeled conjugates are then purified and added to cell culture medium for incubation with target cells. After washing, cells are analyzed by fluorescence microscopy or flow cytometry.
|
| Animal Protocol |
In vivo animal experiments with ATTO 425 NHS ester are not typically performed, as the compound is primarily used as a labeling reagent for in vitro applications. The compound is intended for research use only.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of ATTO 425 NHS ester have not been characterized, as the compound is a research-use fluorescent labeling reagent rather than a drug candidate. The compound has a molecular weight of 463.44 g/mol and should be stored under appropriate conditions, protected from light.
|
| Toxicity/Toxicokinetics |
Toxicological data for ATTO 425 NHS ester has not been systematically evaluated, as the compound is intended for research applications only and not for therapeutic use. Standard laboratory safety precautions should be observed.
|
| Additional Infomation |
ATTO 425-3 is an ethyl pyrrolidone ester. It is functionally related to ATTO 425-2.
ATTO 425 NHS ester is an amine-reactive NHS ester derivative of the blue-fluorescent ATTO 425 dye for labeling proteins, antibodies, and biomolecules. The compound has no clinical or therapeutic applications. |
| Molecular Formula |
C26H30N2O8
|
|---|---|
| Molecular Weight |
498.53
|
| Exact Mass |
498.2
|
| CAS # |
892156-28-4
|
| PubChem CID |
16211368
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.452
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
36
|
| Complexity |
957
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C(C(OCC)=O)=CC2C(=CC3N(CCCC(ON4C(=O)CCC4=O)=O)C(C)(C)CC(C)C=3C=2)O1
|
| InChi Key |
PUEQEMDTFPYCDY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H30N2O8/c1-5-34-24(32)18-12-16-11-17-15(2)14-26(3,4)27(19(17)13-20(16)35-25(18)33)10-6-7-23(31)36-28-21(29)8-9-22(28)30/h11-13,15H,5-10,14H2,1-4H3
|
| Chemical Name |
ethyl 9-[4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutyl]-6,8,8-trimethyl-2-oxo-6,7-dihydropyrano[3,2-g]quinoline-3-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0059 mL | 10.0295 mL | 20.0590 mL | |
| 5 mM | 0.4012 mL | 2.0059 mL | 4.0118 mL | |
| 10 mM | 0.2006 mL | 1.0029 mL | 2.0059 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
